During Thursday’s Current trade, Shares of Big Lots, Inc. (NYSE:BIG), gain 3.05% to $42.24.
Mari Linn Lacovara was given no warning in May 2013 that the decorative oil-filled lamp she bought at a local chain discount store for her Egg Harbor Township home would easily become an explosive device and nearly take her life. After becoming yet another victim of the Big Lots, Inc. exploding tabletop citronella-oil torch, the New Jersey woman and her husband are suing the lamp’s seller and urging tighter controls on the sale of similar products.
According to the complaint (CV-01953-JBS-AMD) filed recently in United States District Court in Camden, Ms. Lacovara, a senior budget office official at the Tropicana, wife of a stepped down firefighter-paramedic, and mother of two, on May 22, 2013 was on her back deck, blowing out the mosaic-style, oil-fueled tabletop torch, which she purchased at the discount Big Lots (BIG) store in nearby Somers Point, when the lamp suddenly exploded.
Big Lots, Inc., through its auxiliaries, operates as a non-traditional, discount retailer in the United States. The company offers products under various merchandising categories, such as food category that comprises beverage and grocery, candy and snacks, and specialty foods departments; consumables category, which comprises health and beauty, plastics, paper, chemical, and pet departments; soft home category that comprises of fashion bedding, utility bedding, bath, window, decorative textile, and area rugs departments; hard home category, counting small appliances, table top, food preparation, stationery, greeting cards, tools, paint, and home maintenance departments; and furniture and home décor category comprising of upholstery, mattress, ready-to-assemble, case goods, home décor, and frames departments.
Shares of Companhia de Saneamento Basico (ADR) (NYSE:SBS), inclined 5.78% to $4.39, during its current trading session.
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (SBS), one of the largest water and sewage services providers in the world based in the number of customers, declares recently its 2Q15 results.
In 2Q15, net operating revenue, counting construction revenue, reached R$ 2.8 billion; a 2.5% enhance contrast to 2Q14.
Costs and expenses, counting construction costs, totaled R$ 2.4 billion, up by 1.5% contrast to R$ 2.3 billion recorded in 2Q14.
Adjusted EBIT, in the amount of R$ 472.5 million, grew 7.6% from R$ 439.1 million recorded in the same quarter of the previous year.
Adjusted EBITDA, in the amount of R$ 756.6 million, raised 14.3% from R$ 661.7 million recorded in 2Q14 (R$ 3,355.1 million in the last 12 months).
Companhia de Saneamento Basico do Estado de Sao Paulo SABESP provides basic and environmental sanitation services; and supplies treated water on a wholesale basis to residential, commercial, industrial, and governmental customers in the state of Sao Paulo. The company operates through two segments, Water and Sewage. It provides water supply; sanitary sewage services; urban rainwater administration and drainage services; urban cleaning services; solid waste administration services; and related activities, counting the planning, operation, maintenance, and commercialization of energy. As of December 31, 2014, the company offered water services through 8.2 million water connections to about 25.3 million people; and sewage services through 6.7 million sewage connections to about 22.4 million people, in addition to operated 70,800 kilometers of water pipes and water transmission lines, and 47,992 kilometers of sewer lines.
Allegheny Technologies Incorporated (NYSE:ATI), during its Thursday’s current trading session gained 4.72% to $18.43.
Faced with a lack of progress in ongoing contract negotiations, Allegheny Technologies Incorporated (ATI) issued recently a lockout notice involving more than 2,000 workers at various facilities. The lockout takes effect Saturday, August 15, 2015. ATI will continue to operate the affected facilities and continue serving customer needs with ATI salaried and non-union employees and temporary professional staffing until a new contract can be finalized with the USW.
ATI began formal negotiations with the USW in May for contracts that expired June 30, 2015. No extensions are in place. The company presented its last, best and final offer to the USW on August 4 with a request that the union accept it by August 10. The USW negotiating committee has not accepted the company’s offer or allowed the ATI employees to vote on it. The company proposal comprises $4,500 in lump-sum payments over the four-year agreement and continued incentive programs for ATI Flat Rolled Products employees, who averaged $94,000 in earnings in 2014. The proposal also comprised of affordable solutions for continued family healthcare, at about half of the cost that the average American worker pays.
ATI began formal negotiations with the USW in May for contracts that expired June 30, 2015. No extensions are in place. The company presented its last, best and final offer to the USW on August 4 with a request that the union accept it by August 10. The USW negotiating committee has not accepted the company’s offer or allowed the ATI employees to vote on it. The company proposal comprises $4,500 in lump-sum payments over the four-year agreement and continued incentive programs for ATI Flat Rolled Products employees, who averaged $94,000 in earnings in 2014. The proposal also comprised of affordable solutions for continued family healthcare, at about half of the cost that the average American worker pays.
Allegheny Technologies Incorporated produces and sells specialty materials and components worldwide. The company operates through two segments, High Performance Materials and Components; and Flat-Rolled Products. The High Performance Materials and Components segment provides various high performance materials, counting titanium and titanium-based alloys; nickel-and cobalt-based alloys and superalloys; zirconium and related alloys, such as hafnium and niobium, advanced powder alloys, and other specialty materials, in long product forms of ingots, billets, bars, rods, wires, shapes and rectangles, and seamless tubes, plus precision forgings, castings, components, and machined parts. This segment serves aerospace and defense, oil and gas, chemical process industry, electrical energy, and medical markets. .
Finally, Omeros Corporation (NASDAQ:OMER), decreased -0.86%, to $16.11.
Omeros Corporation (OMER) declared additional positive data in the company’s Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain. OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, counting atypical hemolytic uremic syndrome (aHUS).
The Phase 2 trial is designed to enroll primarily aHUS patients but can also enroll patients with thrombotic thrombocytopenic purpura (TTP) and hematopoietic stem cell transplant (HSCT)-related TMA. The trial has fully enrolled the first and second cohorts and is presently concluding the third and final planned cohort of its dose-ranging stage. In each three-patient cohort, OMS721 is dosed for four weeks. Data from the first (low-dose) cohort were released on February 19, 2015. Recently the company is releasing data from its second (mid-dose) cohort and data to date from its third (high-dose) cohort.
Three patients were treated in the second or mid-dose cohort, two of whom have aHUS and one with TTP. Both patients with aHUS were on renal dialysis preceding to and at the time of study enrollment. Based on the positive data from the mid-dose cohort, the high-dose cohort was initiated and an aHUS patient has already accomplished the study treatment period. No patient with HSCT-related TMA has yet accomplished dosing with OMS721. The data referenced for all patients comprise measures to one week following the last dose.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
